Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis

By sjmartinez • January 8, 2024

Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165. doi: 10.1177/24755303231201336. Epub 2023 Sep 5. PMID: 38188537; PMCID: PMC10768812.

Tags: Dermatology, deucravacitinib, efficacy, mechanism of action, psoriasis, Publications, review, safety, TYK2, tyrosine kinase

Adult Reactive Infectious Mucocutaneous Eruption (RIME) from Concurrent Adenovirus and Mycoplasma pneumoniae Infections

Li J, Noveir SD, Bouri N, Cheng K, Saini I. Adult Reactive Infectious Mucocutaneous Eruption (RIME) from Concurrent Adenovirus and Mycoplasma pneumoniae Infections. J Gen[...]

TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, Bäriswyl L, Lee DJ, Modlin RL, Z'graggen K, Schenk M. TREM-1 as a[...]

New-Onset Perianal Eroded Lesion in a Pediatric Patient

Yan MJ, Galamgam J, Shen A, Mo J, Hogeling M. New-Onset Perianal Eroded Lesion in a Pediatric Patient. Pediatr Dermatol. 2025 Sep 8. doi: 10.1111/pde.70037.[...]